Research Materials
National Disease Research Interchange
Background:
To facilitate collection of biomedical research materials for FA research, the Fanconi Anemia Research Fund has entered into a partnership with the National Disease Research Interchange (NDRI). NDRI is a 501(c)(3) not-for-profit organization with over 25 years experience in obtaining, storing and distributing human cells, tissues and organs to researchers and scientists (www.ndriresource.org). In conjunction with the NIH Office of Rare Diseases, in 2002 NDRI began to develop a program focused on the unmet needs of the rare disease research community for human organs and tissues. NDRI receives funding for its Rare Disease Program from the National Institutes of Health and the Office of Rare Diseases.
Available Research Materials:
Biomedical samples of Fanconi anemia are available to researchers. Given the rarity of FA, the supply of some biomedical research materials is occasionally limited. Samples are provided only to those researchers who are specifically studying FA. In general, NDRI places around 20,000 biospecimens annually with researchers in academic and government laboratories, as well as those in biomedical and pharmaceutical industries. To that end, the organization works with organ procurement organizations, eye banks, tissue banks and major medical centers in the United States. NDRI has also developed unique programs to serve researchers studying rare diseases, such as Fanconi anemia. Importantly, NDRI has developed mechanisms to aseptically obtain tissues with a very short death-to-preservation interval, making them ideal for cell culture, genomic and proteomic research. NDRI also serves the cancer research community with tumor and normal adjacent tissue specimens preserved at 4°C, frozen, snap-frozen or formalin-fixed/paraffin embedded.
NDRI will strive to meet your exact needs for FA research. Please visit www.ndriresource.org to learn how NDRI can be a valuable resource for your research. To receive an application, contact a Rare Disease Coordinator at raredisease@ndriresource.org or by phone at 1-800-222-6374. The application is also available on NDRI’s website under the Quick Links section.
FA Antibody Project: Antisera Now Available Against Fanconi Anemia Complementation Group Proteins
Fanconi Anemia Research Fund has sponsored the development of high-titer, affinity-purified rabbit polyclonal antisera against the Fanconi anemia complementation group proteins in order to facilitate research on Fanconi anemia.
Affinity-purified antisera are currently available against the following 14 FANC proteins: FANCA, B, C, D2, E, F, G, I, J, M and N, and the deubiquitinating enzyme USP1 protein. Antibodies are being developed to the two most recently identified FANC proteins, FANCO/RAD51C and FANCP/SLX4 proteins and should be available in the second quarter 2012, together with new antisera generated using previously successful epitopes to FANCC, FANCD1/BRCA2 and FANCG. We still have very limited stocks of FANCL antisera kindly provided to us for redistribution.
In addition to affinity-purified antisera, unpurified sera are available for many FANC protein antibody projects listed above for investigators who would like to try alternative purification approaches or uses.
Investigators requesting antisera must complete a request via the website www.ohsu.edu/fa and be willing to meet the FARF’s use agreement. We depend critically on user feedback on these antisera, so will require this as well form all end-users.
General inquiries contact: Ray Monnat, MD, University of Washington, Seattle, Wash.
Telephone: 206-616-7392; Email: monnat@u.washington.edu
Antibody distribution contact: Laura Marquez, Oregon Health & Science University, Portland, Ore.
Telephone: 503-494-6889; Email: marquezl@ohsu.edu
